Isolation method and xeno-free culture conditions influence multipotent differentiation capacity of human Wharton's jelly-derived mesenchymal stem cells

Stem Cell Research and Therapy

Volumn 4, Issue 4, 2013, Pages

  Corotchi, Maria Cristina ^a   Popa, Mirel Adrian ^a   Remes, Anca ^a   Sima, Livia Elena ^b   Gussi, Ilinca ^c   Lupu Plesu, Marilena ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

^b INSTITUTE OF BIOCHEMISTRY OF THE ROMANIAN ACADEMY   (Romania)

^c Clinical Hospital Caritas   (Romania)

Author keywords

Endothelial differentiation; Mesenchymal stem cells; Plasticity; Wharton's jelly; Xeno free medium

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5' NUCLEOTIDASE; ENDOGLIN; HERMES ANTIGEN; THY 1 ANTIGEN; TRANSCRIPTOME;

ADHERENT CELL; ADIPOGENESIS; ARTICLE; BONE DEVELOPMENT; CELL CULTURE; CELL DIFFERENTIATION; CELL EXPANSION; CELL ISOLATION; CELL PROLIFERATION; CHONDROGENESIS; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; EXPLANT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL RESEARCH; WHARTON JELLY; XENO FREE MEDIUM; CULTURE TECHNIQUE; CYTOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; PROCEDURES; UMBILICAL CORD;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; ENDOTHELIAL CELLS; HUMANS; MESENCHYMAL STROMAL CELLS; TRANSCRIPTOME; UMBILICAL CORD;

EID: 84880012896     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt232     Document Type: Article

References (67)

1. The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord. Bongso A, Fong CY, Stem Cell Rev 2013 9 226 240 10.1007/s12015-012-9418-z 23233233
2. Wharton's jelly-derived cells are a primitive stromal cell population. Troyer DL, Weiss ML, Stem Cells 2008 26 591 599 10.1634/stemcells.2007-0439 18065397
3. Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Can A, Karahuseyinoglu S, Stem Cells 2007 25 2886 2895 10.1634/stemcells.2007-0417 17690177 (Pubitemid 350127873)
4. Immune properties of human umbilical cord Wharton's jelly-derived cells. Weiss ML, Anderson C, Medicetty S, Seshareddy KB, Weiss RJ, VanderWerff I, Troyer D, McIntosh KR, Stem Cells 2008 26 2865 2874 10.1634/stemcells.2007-1028 18703664
5. Human Wharton's jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: new perspectives for cellular therapy. La Rocca G, Lo IM, Corsello T, Corrao S, Farina F, Anzalone R, Curr Stem Cell Res Ther 2013 8 100 113 10.2174/1574888X11308010012 23317435
6. Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Fong CY, Chak LL, Biswas A, Tan JH, Gauthaman K, Chan WK, Bongso A, Stem Cell Rev 2011 7 1 16 20602182
7. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, Fu YS, Lai MC, Chen CC, Stem Cells 2004 22 1330 1337 10.1634/stemcells.2004-0013 15579650 (Pubitemid 39636408)
8. Mesenchymalstem cells derived from Wharton's jelly of the umbilical cord: biological properties and emerging clinical applications. Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C, Curr Stem Cell Res Ther 2012 8 144 155
9. Cotransplantation of umbilical cord-derived mesenchymal stem cells promote hematopoietic engraftment in cord blood transplantation: a pilot study. Wu KH, Sheu JN, Wu HP, Tsai C, Sieber M, Peng CT, Chao YH, Transplantation 2013 95 773 777 10.1097/TP.0b013e31827a93dd 23274973
10. New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Anzalone R, Lo Iacono M, Corrao S, Magno F, Loria T, Cappello F, Zummo G, Farina F, La Rocca G, Stem Cells Dev 2010 19 423 438 10.1089/scd.2009.0299 19958166
11. Comparative growth behaviour and characterization of stem cells from human Wharton's jelly. Fong CY, Richards M, Manasi N, Biswas A, Bongso A, Reprod Biomed Online 2007 15 708 718 10.1016/S1472-6483(10)60539-1 18062871 (Pubitemid 350285987)
12. Long-term expansion and pluripotent marker array analysis of Wharton's jelly-derived mesenchymal stem cells. Nekanti U, Rao VB, Bahirvani AG, Jan M, Totey S, Ta M, Stem Cells Dev 2010 19 117 130 10.1089/scd.2009.0177 19619003
13. Endothelial differentiation of Wharton's jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. Chen MY, Lie PC, Li ZL, Wei X, ExpHematol 2009 37 629 640
14. Unique molecular signatures influencing the biological function and fate of post-natal stem cells isolated from different sources. Abu Kasim NH, Govindasamy V, Gnanasegaran N, Musa S, Pradeep PJ, Srijaya TC, Aziz ZA, J Tissue EngRegen Med; 2012 [Epub ahead of print.] 23888354
15. Novel immunomodulatory markers expressed by human WJ-MSC: an updated review in regenerative and reparative medicine. La Rocca G, Corrao S, Lo Iacono M, Corsello T, Farina F, Anzalone R, Open Tissue Eng Regen Med J 2012 5 50 58 10.2174/1875043501205010050
16. Transdifferentiation potentiality of human Wharton's jelly stem cells towards vascular endothelial cells. Alaminos M, Pérez-Köhler B, Garzón I, García-Honduvilla N, Romero B, Campos A, Buján J, J Cell Physiol 2010 223 640 647 20143331
17. Late outgrowth endothelial cells derived from Wharton jelly in human umbilical cord reduce neointimal formation after vascular injury: involvement of pigment epithelium-derived factor. Wang SH, Lin SJ, Chen YH, Lin FY, Shih JC, Wu CC, Wu HL, Chen YL, Arterioscler Thromb Vasc Biol 2009 29 816 822 10.1161/ATVBAHA.109.184739 19342598
18. Simultaneous isolation of vascular endothelial cells and mesenchymal stem cells from the human umbilical cord. Kadam SS, Tiwari S, Bhonde RR, In Vitro Cell Dev Biol Anim 2009 45 23 27 10.1007/s11626-008-9155-4 19057971
19. In vitro and in vivo differentiation of human umbilical cord derived stem cells into endothelial cells. Wu KH, Zhou B, Lu SH, Feng B, Yang SG, Du WT, Gu DS, Han ZC, Liu YL, J Cell Biochem 2007 100 608 616 10.1002/jcb.21078 16960877 (Pubitemid 46180525)
20. A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton's jelly without enzymatic treatment. De Bruyn C, Najar M, Raicevic G, Meuleman N, Pieters K, Stamatopoulos B, Delforge A, Bron D, Lagneaux L, Stem Cells Dev 2011 20 547 557 10.1089/scd.2010.0260 20923277
21. Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation. Pereira WC, Khushnooma I, Madkaikar M, Ghosh K, J Tissue Eng Regen Med 2008 2 394 399 10.1002/term.107 18615777
22. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Weiss ML, Medicetty S, Bledsoe AR, Rachakatla RS, Choi M, Merchav S, Luo Y, Rao MS, Velagaleti G, Troyer D, Stem Cells 2006 24 781 792 10.1634/stemcells.2005-0330 16223852 (Pubitemid 44464783)
23. Method to isolate mesenchymal-like cells from Wharton's jelly of umbilical cord. Seshareddy K, Troyer D, Weiss ML, Methods Cell Biol 2008 86 101 119 18442646
24. Development and characterization of a clinically compliant xeno-free culture medium in good manufacturing practice for human multipotentmesenchymal stem cells. Chase LG, Yang S, Zachar V, Yang Z, Lakshmipathy U, Bradford J, Boucher SE, Vemuri MC, Stem Cells Transl Med 2012 1 750 758 10.5966/sctm.2012- 0072 23197667
25. Development of fully defined xeno-free culture system for the preparation and propagation of cell therapy-compliant human adipose stem cells. Patrikoski M, Juntunen M, Boucher S, Campbell A, Vemuri MC, Mannerstrom B, Miettinen S, Stem Cell Res Ther 2013 4 27 10.1186/scrt175 23497764
26. Large-scale expansion of pre-isolated bone marrow mesenchymal stromal cells in serum-free conditions. Gottipamula S, Muttigi MS, Chaansa S, Ashwin KM, Priya N, Kolkundkar U, Sundar Raj S, Majumdar AS, Seetharam RN, J Tissue Eng Regen Med; 2013 [Epub ahead of print.] 23881832
27. Internalized antigens must be removed to prepare hypoimmunogenicmesenchymal stem cells for cell and gene therapy. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, Hsu SC, Smith J, Prockop DJ, Mol Ther 2004 9 747 756 10.1016/j.ymthe.2004.02.012 15120336 (Pubitemid 38660428)
28. Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions. Santos F, Andrade PZ, Abecasis MM, Gimble JM, Chase LG, Campbell AM, Boucher S, Vemuri MC, Silva CL, Cabral JM, Tissue Eng Part C Methods 2011 17 1201 1210 21895491
29. Umbilical cord Wharton's jelly: a new potential cell source of mesenchymal stromal cells for bone tissue engineering. Hou T, Xu J, Wu X, Xie Z, Luo F, Zhang Z, Zeng L, Tissue Eng Part A 2009 15 2325 2334 10.1089/ten.tea.2008.0402 19231937
30. A comparison of human bone marrow-derived mesenchymal stem cells and human umbilical cord-derived mesenchymal stromal cells for cartilage tissue engineering. Wang L, Tran I, Seshareddy K, Weiss ML, Detamore MS, Tissue Eng Part A 2009 15 2259 2266 10.1089/ten.tea.2008.0393 19260778
31. Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells. Wang L, Ott L, Seshareddy K, Weiss ML, Detamore MS, Regen Med 2011 6 95 109 10.2217/rme.10.98 21175290
32. CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential. Conconi MT, Burra P, Di Liddo R, Calore C, Turetta M, Bellini S, Bo P, Nussdorfer GG, Parnigotto PP, Int J Mol Med 2006 18 1089 1096 17089012
33. Use of poly(DL-lactide-epsilon-caprolactone) membranes and mesenchymal stem cells from the Wharton's jelly of the umbilical cord for promoting nerve regeneration in axonotmesis: in vitro and in vivo analysis. Gartner A, Pereira T, Armada-da-Silva PA, Amorim I, Gomes R, Ribeiro J, Franca ML, Lopes C, Porto B, Sousa R, Bombaci A, Ronchi G, Fregnan F, Varejao AS, Luis AL, Geuna S, Mauricio AC, Differentiation 2012 84 355 365 10.1016/j.diff.2012.10.001 23142731
34. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis. Tsai PC, Fu TW, Chen YM, Ko TL, Chen TH, Shih YH, Hung SC, Fu YS, Liver Transpl 2009 15 484 495 10.1002/lt.21715 19399744
35. Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Anzalone R, Lo IM, Loria T, Di SA, Giannuzzi P, Farina F, La Rocca G, Stem Cell Rev 2011 7 342 363 10.1007/s12015-010-9196-4 20972649
36. Engineering of biologically active living heart valve leaflets using human umbilical cord-derived progenitor cells. Schmidt D, Mol A, Odermatt B, Neuenschwander S, Breymann C, Gössi M, Genoni M, Zund G, Hoerstrup SP, Tissue Eng 2006 12 3223 3232 10.1089/ten.2006.12.3223 17518636 (Pubitemid 44846426)
37. The human umbilical vein with Wharton's jelly as an allogeneic, acellular construct for vocal fold restoration. Chan RW, Rodriguez ML, McFetridge PS, Tissue Eng Part A 2009 15 3537 3546 10.1089/ten.tea.2009.0064 19456236
38. Minimal criteria for defining multipotentmesenchymal stromal cells. The International Society for Cellular Therapy position statement. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E, Cytotherapy 2006 8 315 317 10.1080/14653240600855905 16923606 (Pubitemid 44269669)
39. Engineered adipose tissue from human mesenchymal stem cells maintains predefined shape and dimension: implications in soft tissue augmentation and reconstruction. Alhadlaq A, Tang M, Mao JJ, Tissue Eng 2005 11 556 566 10.1089/ten.2005.11.556 15869434 (Pubitemid 40632571)
40. GATA2 functions at multiple steps in hemangioblast development and differentiation. Lugus JJ, Chung YS, Mills JC, Kim SI, Grass J, Kyba M, Doherty JM, Bresnick EH, Choi K, Development 2007 134 393 405 10.1242/dev.02731 17166922
41. VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies. Eriksson U, Alitalo K, Nat Med 2002 8 775 777 10.1038/nm0802-775 12152025
42. Xeno-free proliferation of human bone marrow mesenchymal stem cells. Miwa H, Hashimoto Y, Tensho K, Wakitani S, Takagi M, Cytotechnology 2012 64 301 308 10.1007/s10616-011-9400-7 22002865
43. Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Chevallier N, Anagnostou F, Zilber S, Bodivit G, Maurin S, Barrault A, Bierling P, Hernigou P, Layrolle P, Rouard H, Biomaterials 2010 31 270 278 10.1016/j.biomaterials.2009.09.043 19783038
44. Functional module analysis reveals differential osteogenic and stemness potentials in human mesenchymal stem cells from bone marrow and Wharton's jelly of umbilical cord. Hsieh JY, Fu YS, Chang SJ, Tsuang YH, Wang HW, Stem Cells Dev 2010 19 1895 1910 10.1089/scd.2009.0485 20367285
45. [ Comparison of the biological characteristics of serum-free and fetal bovine serum-contained medium cultured umbilical cord-derived mesenchymal stem cells]. Yang T, Chen GH, Xue SL, Qiao M, Liu HW, Tian H, Qiao SM, Chen F, Chen ZZ, Sun AN, Wu DP, ZhonghuaXue Ye XueZaZhi 2012 33 715 719
46. Human mesenchymal stem cells from the umbilical cord matrix: successful isolation and ex vivo expansion using serum-/xeno-free culture media. Simoes IN, Boura JS, dos Santos F, Andrade PZ, Cardoso CM, Gimble JM, da Silva CL, Cabral JM, Biotechnol J 2013 8 448 458 10.1002/biot.201200340 23420807
47. The heterogeneity of human mesenchymal stem cell preparations-evidence from simultaneous analysis of proteomes and transcriptomes. Wagner W, Feldmann RE Jr, Seckinger A, Maurer MH, Wein F, Blake J, Krause U, Kalenka A, Bürgers HF, Saffrich R, Wuchter P, Kuschinsky W, Ho AD, Exp Hematol 2006 34 536 548 10.1016/j.exphem.2006.01.002 16569600
48. Replicative senescence of mesenchymal stem cells: a continuous and organized process. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V, Blake J, Pfister S, Eckstein V, Ho AD, PLoS One 2008 3 2213 10.1371/journal.pone.0002213 18493317
49. The origins of mesenchymal stromal cell heterogeneity. Pevsner-Fischer M, Levin S, Zipori D, Stem Cell Rev 2011 7 560 568 10.1007/s12015-011-9229-7 21437576
50. Identification of subpopulations in mesenchymal stem cell-like cultures from human umbilical cord. Majore I, Moretti P, Hass R, Kasper C, Cell Commun Signal 2009 7 6 10.1186/1478-811X-7-6 19302702
51. The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extracellular matrix. Zhu H, Mitsuhashi N, Klein A, Barsky LW, Weinberg K, Barr ML, Demetriou A, Wu GD, Stem Cells 2006 24 928 935 10.1634/stemcells.2005-0186 16306150 (Pubitemid 44464726)
52. Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy. Phinney DG, Cell Cycle 2007 6 2884 2889 10.4161/cc.6.23.5095 18000405
53. Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Digirolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ, Br J Haematol 1999 107 275 281 10.1046/j.1365-2141.1999. 01715.x 10583212 (Pubitemid 29530211)
54. Effect of anatomical origin and cell passage number on the stemness and osteogenic differentiation potential of canine adipose-derived stem cells. Requicha JF, Viegas CA, Albuquerque CM, Azevedo JM, Reis RL, Gomes ME, Stem Cell Rev 2012 8 1211 1222 10.1007/s12015-012-9397-0 22773405
55. Effects of serial passaging on the adipogenic and osteogenic differentiation potential of adipose-derived human mesenchymal stem cells. Wall ME, Bernacki SH, Loboa EG, Tissue Eng 2007 13 1291 1298 10.1089/ten.2006.0275 17518709 (Pubitemid 46986729)
56. Analysis of differentiation potentials and gene expression profiles of mesenchymal stem cells derived from periodontal ligament and Wharton's jelly of the umbilical cord. Yu S, Long J, Yu J, Du J, Ma P, Ma Y, Yang D, Fan Z, Cells Tissues Organs 2013 197 209 223 10.1159/000343740 23257615
57. Human chorionic-plate-derived mesenchymal stem cells and Wharton's jelly-derived mesenchymal stem cells: a comparative analysis of their potential as placenta-derived stem cells. Kim MJ, Shin KS, Jeon JH, Lee DR, Shim SH, Kim JK, Cha DH, Yoon TK, Kim GJ, Cell Tissue Res 2011 346 53 64 10.1007/s00441-011- 1249-8 21987220
58. Upregulation of miR-22 promotes osteogenic differentiation and inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells by repressing HDAC6 protein expression. Huang S, Wang S, Bian C, Yang Z, Zhou H, Zeng Y, Li H, Han Q, Zhao RC, Stem Cells Dev 2012 21 2531 2540 10.1089/scd.2012.0014 22375943
59. Use of proteomic differential displays to assess functional discrepancies and adjustments of human bone marrow- and Wharton jelly-derived mesenchymal stem cells. Kuo HC, Chiu CC, Chang WC, Sheen JM, Ou CY, Kuo HC, Chen RF, Hsu TY, Chang JC, Hsaio CC, Wang FS, Huang CC, Huang HY, Yang KD, J Proteome Res 2011 10 1305 1315 10.1021/pr101057w 21155588
60. Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Trochon V, Mabilat C, Bertrand P, Legrand Y, Smadja-Joffe F, Soria C, Delpech B, Lu H, Int J Cancer 1996 66 664 668 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4 8647630 (Pubitemid 26197930)
61. Involvement of endothelial CD44 during in vivo angiogenesis. Cao G, Savani RC, Fehrenbach M, Lyons C, Zhang L, Coukos G, Delisser HM, Am J Pathol 2006 169 325 336 10.2353/ajpath.2006.060206 16816384
62. Identification of the hemogenic endothelial progenitor and its direct precursor in human pluripotent stem cell differentiation cultures. Choi KD, Vodyanik MA, Togarrati PP, Suknuntha K, Kumar A, Samarjeet F, Probasco MD, Tian S, Stewart R, Thomson JA, Slukvin II, Cell Rep 2012 2 553 567 10.1016/j.celrep.2012.08.002 22981233
63. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE, Circulation 2004 109 1543 1549 10.1161/01.CIR.0000124062.31102.57 15023891 (Pubitemid 38420184)
64. Implantation of adipose-derived regenerative cells enhances ischemia-induced angiogenesis. Kondo K, Shintani S, Shibata R, Murakami H, Murakami R, Imaizumi M, Kitagawa Y, Murohara T, Arterioscler Thromb Vasc Biol 2009 29 61 66 10.1161/ATVBAHA.108.166496 18974384
65. Proangiogenic features of Wharton's jelly-derived mesenchymal stromal/stem cells and their ability to form functional vessels. Choi M, Lee HS, Naidansaren P, Kim H-K,Cha J-H, Ahn H-Y, Yang PI, Shin J-C, Joe YA, Int J Biochem Cell Biol 2012 45 560 570 23246593
66. Mesoderm-derived stem cells: the link between the transcriptome and their differentiation potential. De Kock J, Najar M, Bolleyn J, Al Battah F, Rodrigues RM, Buyl K, Raicevic G, Govaere O, Branson S, Meganathan K, Gaspar JA, Roskams T, Sachinidis A, Lagneaux L, Vanhaecke T, Rogiers V, Stem Cells Dev 2012 21 3309 3323 10.1089/scd.2011.0723 22651824
67. Human umbilical cord mesenchymal stem cells derived from Wharton's jelly differentiate into cholinergic-like neurons in vitro. Liang J, Wu S, Zhao H, Li SL, Liu ZX, Wu J, Zhou L, Neurosci Lett 2013 532 59 63 23178189